Yifan Pharmaceuticals: It is expected that the sales volume of its core product Yilishu will further increase in 2025.

Yifan Pharmaceuticals introduced the sales situation of its core product Yilishu during an online meeting with institutional investors on June 2nd. In the domestic market, Yilishu passed the national medical insurance negotiation by the end of 2023 and saw a significant increase in sales in its first year on medical insurance in 2024, with over 270,000 units shipped throughout the year. Based on the sales milestone payments confirmed by the company in 2024, Yilishu's net sales in China in 2024 exceeded 500 million yuan. According to the company's production schedule, sales are expected to further increase in 2025. In the U.S. market, the original plan was to list in the U.S. by the end of July 2024, but as the MAH holder, the company experienced packaging problems due to lack of experience and delays in the overseas supply chain. By the end of May 2025, Yilishu had successfully been shipped from Germany to the U.S., with sales expected to be achieved in mid-June.